[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial


Dr Marie-Edith Bonneterre

Hemerion appoints Dr Marie-Edith Bonneterre as Chief Medical Officer

Dr Marie-Edith Bonneterre has been appointed Chief Medical Officer (CMO) at Hemerion on September 19, 2023, to steer the medical and clinical strategy of our innovative therapeutic solutions.

A specialist in cancer treatment

Trained as a medical oncologist, Marie-Edith Bonneterre quickly acquired solid experience in innovative cancer treatments, with her leadership of clinical trials at the Oscar Lambret Center in Lille, one of France’s leading cancer centers.

In close contact with patients, Marie-Edith was able to follow the clinical development of innovative molecules of all types, at every stage of clinical development.

Cross-disciplinary, international expertise in clinical development

As a clinical development specialist, Marie-Edith Bonneterre has worked in a wide range of complementary structures and environments: the pharmaceutical industry (Sanofi), start-ups (PharmaMar), Contract Research Organizations (PPD, Syneos, Ergomed) and regulatory bodies (ANSM, European Commission).

This wide-ranging experience gives Hemerion a truly transversal vision of clinical development, perfectly suited to the hybrid nature of its combined Drug + Device therapeutic solutions.

Dr Marie-Edith Bonneterre also brings to Hemerion’s teams an international vision of clinical development, acquired in Europe and the United States: an essential asset in making the Heliance® / Pentalafen® combination therapy a new international standard of care in the treatment of glioblastoma.

Objective: accelerate time-to-market

Having piloted dozens of clinical trials in oncology, Dr Marie-Edith Bonneterre has developed a global, cross-disciplinary vision of cancer treatments, at clinical, medical and strategic levels.

She also brings to Hemerion a wealth of experience in the management of clinical trials: a considerable asset for accelerating the time-to-market of Hemerion’s first solution for the treatment of glioblastoma.

The first objectives are to launch the next clinical study in early 2024 and optimize the implementation of market-access phases.

I had no hesitation in accepting the mission proposed by the Hemerion founders. Their therapeutic solutions for glioblastoma are both highly original and extremely promising! Completely integrated into the standard of care, they intervene before the metastatic stage and recurrence, when the cancer can be fought most effectively. These treatments are a source of great hope for caregivers and patients alike: we need to move as quickly as possible to make them available worldwide.

Marie-Edith Bonneterre, CMO, Hemerion